A Food and Drug Administration advisory committee will review CombinatoRx's (Nasdaq: CRXX) pain treatment Exalgo. The stock price dropped 36 cents to close at $1.73.
FDA To Review CombinatoRx's Pain Treatment
September 22, 2009 at 18:26 PM EDT
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.